mHealth as Effective as Clinic-Based Intervention for People with Serious Mental Illness

A mobile health (mHealth) intervention was found to be as effective as a clinic-based group intervention for people with serious mental illness in a new study published online in Psychiatric Services. In a randomized controlled trial, researchers compared an mHealth approach (FOCUS), using mobile phones to deliver intervention, to a more traditional clinic-based group intervention, the Wellness Recovery Action Plan (WRAP). The study, led by Dror Ben-Zeev, Ph.D., with the University of Washington, Seattle, looked at the differences in treatment engagement, satisfaction, improvement in symptoms, recovery and quality of life.

Participants included 163 individuals with long-term, serious mental illness, including schizophrenia, schizoaffective disorder, bipolar disorder and major depressive disorder. Participants were randomly assigned to either the smartphone-based FOCUS group or the clinic-based WRAP group, and the interventions lasted 12 weeks. Assessments were done pre-intervention, post-intervention, and at a six-month follow-up.

FOCUS is a smartphone-delivered intervention for people with serious mental illness with three main components: the FOCUS app, a clinician dashboard, and support from an mHealth specialist. It includes daily self-assessment prompts and content that can be accessed 24 hours a day as either brief video or audio clips, or a series of written material with images. FOCUS users' responses to daily self-assessments are relayed to the support specialist, who holds weekly calls with each participant.

WRAP is a widely used evidence-based, group self-management intervention led by trained facilitators with lived experience of mental illness. It emphasizes individuals' equipping themselves with personal wellness tools focusing on recovery concepts, such as hope and self-advocacy.

On random assignment, participants in the mHealth group were more likely to begin mental health treatment (90 percent), compared with WRAP (58 percent). Significantly more FOCUS participants completed eight or more weeks of treatment, but the percentage completing the full 12 weeks was similar for the two groups. After the intervention, participants in both groups improved significantly. WRAP participants showed significant improvements in recovery at the end of treatment (three months), and mHealth participants showed significant improvement in recovery and quality of life at six months.

Participants in both groups reported high satisfaction, noting the interventions were enjoyable and interactive and helped them feel better. Age, gender, race, having previous experience with smartphones, and number of previous psychiatric hospitalizations were not associated with recovery outcomes.

The authors report this is the first randomized controlled trial comparing a smartphone intervention to a clinic-based intervention involving individuals with schizophrenia spectrum disorders.

Ben-Zeev D, Brian RM, Jonathan G, Razzano L, Pashka N, Carpenter-Song E, Drake RE, Scherer EA.
Mobile Health (mHealth) Versus Clinic-Based Group Intervention for People With Serious Mental Illness: A Randomized Controlled Trial.
Psychiatr Serv. 2018 May 25:appips201800063. doi: 10.1176/appi.ps.201800063.

Most Popular Now

What the Radiologist should Know about A…

This paper aims to provide a review of the basis for application of AI in radiology, to discuss the immediate ethical and professional impact in radiology, and to consider possible...

The Mobile Game that can Detect Alzheime…

A specially designed mobile phone game can detect people at risk of Alzheimer's - according to new research from the University of East Anglia. Researchers studied gaming data from an...

Hospital Diagnoses Critically Ill Childr…

The Rady Children’s Hospital (San Diego, USA) used Moon, software developed by the Leuven-based (Belgium) company Diploid. Moon is the first software worldwide to use Artificial Intelligence (AI) for the...

AstraZeneca Starts Artificial Intelligen…

AstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic...

Novartis Presents First-of-its-Kind Algo…

Novartis today announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool aims to support and facilitate a discussion between...

Bayer Joins Sensyne Health Consortium Wo…

Sensyne Health plc (LSE: SENS), the British clinical AI technology company, and Bayer, the life sciences company, announce that Bayer has become Sensyne Health's preferred pharmaceutical partner to work together...

Red Hat Helps Public Health England Use …

Red Hat, Inc. (NYSE: RHT), the world's leading provider of open source solutions, announced that Public Health England (PHE), an executive agency of the Department of Health and Social Care...

Chipmunk Health Chooses Philips HealthSu…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that telehealth service provider Chipmunk Health, with locations in the Netherlands and Canada, is leveraging the capabilities...

Siemens Healthineers and European Societ…

With their first course under the heading "Intelligence. Innovation. Imaging - The perfect vision of AI," held in Barcelona on April 5-6, Siemens Healthineers and the European Society of Radiology...

Mobile Prenatal App Shown to Reduce in-P…

Using the mobile app Babyscripts reduced in-person prenatal care visits while maintaining patient and provider satisfaction, according to research published in JMIR mHealth and uHealth by physician researchers from the...